Drug firm Cadila Healthcare today reported a 32.48 per cent rise in its consolidated net profit to Rs 503.3 crore for the second quarter ended September 30, mainly on account of robust sales in the US and India. The company had posted a net profit of Rs 379.9 crore for the corresponding period of the previous fiscal, Cadila Healthcare said in a BSE filing. Consolidated total revenue from operations also rose to Rs 3,234 crore for the quarter under consideration as against Rs 2,403.5 crore in the same period a year ago. The company's sales in the US rose by 66 per cent to Rs 1,644 crore for the quarter ended September 30, Cadila Healthcare said. The Indian formulations business also grew by 15 per cent, excluding the excise duty, to Rs 895 crore, it added. "During the quarter, the company launched four new products in the US, including Mesalamine delayed release 1.2 g tablets (generic version of Lialda) with a 180 days exclusivity," Cadila Healthcare said. Shares of Cadila Healthcare were today closed at Rs 448.50 per scrip on BSE, down 0.50 per cent from its previous close.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)